KDM4B and endometrial cancer: One study exploring the role of androgen receptor (AC) in endometrial cancer suggested that KDM4B together with AR can activate the well-recognised oncogene, MYC, by removing H3K9me3 marks in endometrial cancer cells with high basal levels of AR [28].